NICE backing for Astella's Xospata

17th July 2020 Uncategorised 0

The drug is considered a cost-effective treatment for relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia

More: NICE backing for Astella's Xospata
Source: News